logo
Plus   Neg
Share
Email

Roche Launches Elecsys Anti-p53 Immunoassay To Diagnose Several Prevalent Cancers

Roche (RHHBY) announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. The test is used to aid physicians to diagnose throat cancer, bowel cancer and breast cancer in patients.

Roche said the new Elecsys Anti-p53 immunoassay uses the electrochemiluminescence immunoassay ECLIA technology and is intended for use on cobas e immunoassay analyzers. It is a high precision immunoassay, with a low turn-around time for testing.

The Elecsys Anti-p53 immunoassay is now available for all markets accepting the CE Mark.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast-food giant McDonald's said it will be raising hourly wages for more than 36,500 hardworking employees at McDonald's-owned restaurants by an average of 10 percent to make it among the industry-leading pay and benefits package. These increases, which have already begun, will be rolled out over the next several months. Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints,... General Mills Inc. (GIS) agreed to buy Tyson Foods' (TSN) pet treats business for $1.2 billion in cash, the companies said in a statement on Friday. The transaction includes the Nudges, Top Chews and True Chews brands. General Mills will also acquire a manufacturing facility in Independence, Iowa.
Follow RTT